Diaceutics PLC Notice of Results (3799R)
March 08 2021 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 3799R
Diaceutics PLC
08 March 2021
8 March 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Notice of results
Analyst & investor briefing
Diaceutics PLC (AIM: DXRX), announces it will release its
preliminary results for the year ended 30 December 2020 on Monday,
15 March 2021.
Analyst briefing
The Company will host a ZOOM briefing for analysts which will
take place at 9.30am on Monday, 15 March 2021. If you would like to
register to dial in, please contact Walbrook PR on 020 7933 8780 or
email diaceutics@walbrookpr.com.
Investor briefing
Peter Keeling, CEO and Philip White, CFO will provide a live
presentation on the preliminary results via the Investor Meet
Company platform at 3pm on Wednesday, 17 March 2021.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Diaceutics PLC via:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Investors who already follow Diaceutics PLC on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0) 20 7391 8900
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - the world's first
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Group,
listed on the AIM Market of the London Stock Exchange, has created
commercially useful data sets for every precision medicine that has
come to market. We have built the world's largest repository of
diagnostic testing data with a growing network of 2500 labs in 51
countries. www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUVVSRAWUORAR
(END) Dow Jones Newswires
March 08, 2021 02:00 ET (07:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024